Category Archives: Cell Biology

The Growth Factors Market To Show Constructive Disruption With ~ US$ 2.5 Bn – TechnoWeekly

Market Report Summary

For Full Information -> Click Here

Read Full Press Release Below

According to the latest market report published by PMR on thegrowth factors marketduring2014 2018and forecast for2019 2029,the global growth factors market is projected to reach~ US$ 2.5 Bn by the end of 2029.The growth factors market is expected to grow with a CAGR of~ 8 %during the forecast period2019-2029.

Growth factors are gaining high demand for cell culture-based research in the field of oncology, wound management, cardiovascular, and other medical fields. The growth factors market is expected to grow at a significant rate due to the growing demand for stem cell biology research.

Get Sample Copy of Report @ https://www.persistencemarketresearch.com/samples/4456

Company Profiles

Increasing Life Science Research Funding Favors the Growth of the Market

Growth factors & cytokines play an important role in life science-based research. Various government, private, and commercial organizations are providing funding for life science-based research for the development of new products to reduce illness and economic burden. Investments in R&D are likely to increase in countries such as China, India, and South Korea.

Moreover, the increasing demand for growth factors in tissue regeneration and regenerative medicines is also expected to propel the growth of the global growth factors market. The global growth factors market is expected to witness significant growth over the forecast period due to increasing oncological and stem cell biology research funding, and the development of new products for wound management.

However, the high cost of some growth factors and lack of skilled professionals are among the major factors hindering the growth of the growth factors market.

Get To Know Methodology of Report @ https://www.persistencemarketresearch.com/methodology/4456

Interleukins to Gain Significant Market Value Shares in the Global Growth Factors Market

Based on product type, the global growth factors market has been segmented into Interleukin (ILs), Epidermal Growth Factors (EGFs), Transforming Growth Beta Factor (TGF-beta), Fibroblast Growth Factors (FGFs), Insulin-Like Growth Factors (IGFs), Platelet-Derived Growth Factors (PDGFs), Hepatocyte Growth Factors (HGFs), Vascular Endothelial Growth Factors (VEGFs), Tumor Necrosis Factors (TNFs), and others.

In terms of revenue, the Interleukins (ILs) are expected to hold a prominent share in the growth factors market revenues, through the end of forecast period.

Based on application, the global growth factors market has been segmented into oncology, dermatology, cardiovascular disease & diabetes, hematology, wound healing, cell culture, and others. Cell culture will remain the most prominent application area of growth factors, as indicated by PMRs study. By end user, the global growth factors market continues to witness a strong boost through the growing demand from contract research organizations, pharmaceutical & biotechnology companies, and research centers & academic institutes.

Access Full Report @ https://www.persistencemarketresearch.com/checkout/4456

North America Holds a Prominent Revenue Share in the Global Growth Factors Market

Geographically, the global growth factors market has been segmented into East Asia, South Asia, Oceania, North America, Latin America, Europe, and the Middle East & Africa. North America holds a prominent revenue share in the global growth factors market as of 2018.

The East Asia growth factors market is expected to grow with a significant growth rate over the forecast period. Countries such as the U.S., China, Germany, Japan, the UK, France, and India accounted for a significant revenue share in the global growth factors market in 2018.

Explore Extensive Coverage of PMR`sLife Sciences & Transformational HealthLandscape

Persistence Market Research (PMR) is a third-platform research firm. Our research model is a unique collaboration of data analytics and market research methodology to help businesses achieve optimal performance.

To support companies in overcoming complex business challenges, we follow a multi-disciplinary approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying real-time data collection, big data, and customer experience analytics, we deliver business intelligence for organizations of all sizes.

Our client success stories feature a range of clients from Fortune 500 companies to fast-growing startups. PMRs collaborative environment is committed to building industry-specific solutions by transforming data from multiple streams into a strategic asset.

Contact us:

Ashish KoltePersistence Market ResearchAddress 305 Broadway, 7th FloorNew York City,NY 10007 United StatesU.S. Ph. +1-646-568-7751USA-Canada Toll-free +1 800-961-0353Sales[emailprotected]Website https://www.persistencemarketresearch.com

Read this article:
The Growth Factors Market To Show Constructive Disruption With ~ US$ 2.5 Bn - TechnoWeekly

90% efficacy for Pfizers COVID-19 mRNA vaccine is striking. But we need to wait for the full data – Australian Times

Harry Al-Wassiti, Monash University; Colin Pouton, Monash University, and Kylie Quinn, RMIT University

German biotech company BioNTech and US pharmaceutical Pfizer announced on Monday promising early results from their phase 3 clinical trial for a vaccine against SARS-CoV-2, the virus that causes COVID-19.

These early results are what is known as an interim analysis. Its an early look at the data before a study is complete, to understand if there is any indication of whether the vaccine might work.

Currently, this trial has enrolled 43,538 volunteers, giving half the volunteers two doses of the vaccine and the other half two doses of a placebo. These volunteers then continued their normal lives, but they were monitored for any symptoms that could be COVID-19, with testing to confirm.

Analysis of 94 volunteers with confirmed COVID-19 suggests the vaccine has an efficacy of over 90%.

This means that if you took ten people who were going to get sick from COVID-19 and vaccinated them, only one out of ten would now get sick.

There is more data to come. This is a press release and the data have not undergone peer-review through scientific publication, although it has been assessed by an independent monitoring board. The study also wont be complete until 164 volunteers have confirmed COVID-19, and the estimate of efficacy may therefore change. Finally, the volunteers must be monitored for a defined period of time after vaccination for any side effects and this must be completed.

Important questions also remain. Its unclear how long protection will last, as this study has only been underway for three months. Its unclear if this vaccine protects against severe disease or if this vaccine will work equally well in everyone. For example, a phase 1 clinical trial with this vaccine showed that immune responses were lower in older people.

But 90% efficacy is striking. To give some context, the US Food and Drug Administration indicated they would licence a SARS-CoV-2 vaccine with 50% efficacy. The flu vaccine often provides around 60% efficacy and the mumps vaccine, which is currently the fastest vaccine ever made at four years, provides around 88% efficacy.

The BioNTech/Pfizer vaccine could outstrip that, after just nine months of development. This level of efficacy means virus transmission could be very effectively controlled.

That has the research community excited. It bodes well for other vaccines currently being tested for SARS-CoV-2 and we could end up with multiple successful vaccines. This would be great because some might work better in certain populations, like older people.

Multiple vaccines could also be manufactured using a broad range of established infrastructure, which would accelerate vaccine distribution.

The BioNTech/Pfizer vaccine is whats called an mRNA vaccine.

As this article by Associate Professor Archa Fox, an expert on molecular cell biology from the University of Western Australia, explains:

mRNA vaccines are coated molecules of mRNA, similar to DNA, that carry the instructions for making a viral protein.

After injection into muscle, the mRNA is taken up by cells. Ribosomes, the cells protein factories, read the mRNA instructions and make the viral protein. These new proteins are exported from cells and the rest of the immunisation process is identical to other vaccines: our immune system mounts a response by recognising the proteins as foreign and developing antibodies against them.

The problem is Australia cant make mRNA vaccines onshore yet.

The Australian government has an agreement for ten million doses of the BioNTech/Pfizer vaccine. Since this vaccine requires two doses, this agreement is sufficient for five million Australians. Its unclear how long it will take until any vaccine is widely available, but we may hear more about this in the coming weeks and months.

The vaccine requires storage at a temperature below -60. This will certainly be a challenge for shipping to Australia and local distribution, although not impossible. One solution to this problem is to form vaccination centres to roll out the vaccine once it becomes available. In a briefing by Pfizer, the company said it will use ultra-low temperature shipment strategies and the vaccine can then be distributed on dry-ice.

Currently, Australia has no capacity to produce mRNA on a commercial scale given the technologys novelty. But we (the authors) and others have been working to coordinate and build the manufacturing capacity in Australia for future mRNA vaccine and therapeutics. With financial support aimed at private-public mRNA manufacturing collaboration, Australia can equip itself with this vital technological asset.

Harry Al-Wassiti, Bioengineer and Research Fellow, Monash University; Colin Pouton, Professor of Pharmaceutical Biology, Monash University, and Kylie Quinn, Vice-Chancellors Research Fellow, School of Health and Biomedical Sciences, RMIT University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Read more:
90% efficacy for Pfizers COVID-19 mRNA vaccine is striking. But we need to wait for the full data - Australian Times

Mimicking the early development of the heart – Tech Explorist

Once upon a time, growing organs in the lab were science fiction. But now, methods such as stem cell biology and tissue engineering have turned that fiction into reality with the advent of organoids.

Organoids are tiny lab-grown tissues and organs that are anatomically correct and physiologically functional.

Recently, the lab of Matthias Ltolf at the School of Life Sciences at EPFL has successfully produced a mouse heart organoid in its early embryonic stages. Scientists grew organoids from mouse embryonic stem cells, which, under the right conditions, can self-organize into structures that mimic aspects of the architecture, cellular composition, and function of tissues found in real organs.

Placed in cell-culture under specific conditions, the embryonic stem cells from a three-dimensional aggregate called a gastruloid, which can follow the mouse embryos developmental phases.

This studys idea was that the mouse gastruloid could be utilized to mimic the beginning phases of heart development in the embryo. This is a new use of organoids, which are commonly developed to mimic adult tissues and organs.

Also, there are three features of mouse gastruloids that make them a suitable template for mimicking embryonic development: they establish a body plan like real embryos. They show similar gene expression patterns. And when it comes to the heart, which is the first organ to form and function in the embryo, the mouse gastruloid also preserves important tissue-tissue interactions necessary to grow one.

Equipped with this, the scientists exposed mouse embryonic stem cells to a cocktail of three factors known to promote heart growth. Following 168 hours, the subsequent gastruloids gave early heart development indications: they expressed several genes that regulate cardiovascular development in the embryo. They even generated what resembled a vascular network.

Importantly, scientists found that the gastruloids developed what they call an anterior cardiac crescent-like domain. This structure produced a beating heart tissue, similar to the embryonic heart. As the muscle cells of the embryonic heart, the beating compartment was also sensitive to calcium ions.

Giuliana Rossi, a post-doctoral researcher from Ltolfs laboratory, said,Opening up an entirely new dimension to organoids, the breakthrough work shows they can also be used to mimic embryonic stages of development. One of the advantages of embryonic organoids is that, through the co-development of multiple tissues, they preserve crucial interactions that are necessary for embryonic organogenesis.

The emerging cardiac cells are thus exposed to a context similar to the one that they encounter in the embryo.

The study was conducted in collaboration with Viventis Microscopy, EPFL Bioimaging and Optics Platform, Institut de Biologie du Dveloppement de Marseille, Johns Hopkins University School of Medicine, EPFL Institute of Chemical Sciences and Engineering.

See the rest here:
Mimicking the early development of the heart - Tech Explorist

Global Live Cell Imaging Consumables Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2025 – The Courier

Global Live Cell Imaging Consumables Market 2020 by Manufacturers, Type and Application, Forecast to 2025 contains an extremely knowledgeable and in-depth evaluation of the present industrial conditions along with market size, estimated from 2020 to 2025. The report encompasses several factors such as global manufacturers, market size, and market factors that affect global contributions. The report discusses factors related to current industry conditions, levels of growth of the industry, demands, business-oriented approaches used by the manufacturers of the Live Cell Imaging Consumables industry in brief about distinct tactics and futuristic prospects. The research throws light on an in-depth competitive landscape, defined growth opportunities, market share coupled with product type and applications, key companies responsible for the production.

The study report analyzes the past market condition and forecasts potential prospects based on comprehensive analysis. The report provides the extensive market share, growth, trends, and forecasts for the 20202025 period. It then studies recent trends, development status, market dynamics (drivers, restraints, and opportunities), supply chain, and competitive landscape. The research report concentrates on leading global players in the global Live Cell Imaging Consumables market report, which includes details such as company profiles, product picture, and specification, creation of R&D, production capability cost, revenue, and contact information. The report is divided into major categories comprising product, distribution channel, application, and end-users.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/66971

Report Synopsis:

Inputs from industry experts have been collected to deliver detailed market analysis. The report encapsulates factors such as market outline, type-based analysis of global Live Cell Imaging Consumables market, application analysis, and end-use. The market analysis report offers market share, demand, and supply ratio, supply chain analysis, and import/export details.

List of top key-players/leading manufacturers of the market: Carl Zeiss AG (Germany), Olympus Corporation (Japan), Molecular Devices, LCC (US), Leica Microsystems (Germany), Becton, Dickinson and Company (US), Nikon Corporation (Japan), Thermo Fisher Scientific, Inc.(US), GE Healthcare (U.K.), PerkinElmer, Inc. (US), Sigma Aldrich Corporation (US)

The most important types of products covered in this report are: Assay Kits, Reagents, Media, Others

The most widely used downstream fields covered in this report are: Cell Biology, Stem Cells, Developmental Biology, Drug Discovery

Regional Overview:

Experts have offered details on the current and the forecast demand made by the main regions. The report also offers information on the unexplored areas in these regions to help the producers to plan promotional strategies and create demand for their new and updated products. Moreover, global Live Cell Imaging Consumables market size, share, supply, demand, consumption, price, import, export, type, and application segment information by region has been included in the report.

It also provides market size and forecast estimates from the year 2020 to 2025 with respect to major regions, namely; North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/66971/global-live-cell-imaging-consumables-market-2020-by-manufacturers-type-and-application-forecast-to-2025

Research Objectives:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketsandresearch.biz), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketsandresearch.bizWeb: http://www.marketsandresearch.biz

Read more from the original source:
Global Live Cell Imaging Consumables Market 2020 Analysis, Types, Applications, Forecast and COVID-19 Impact Analysis 2025 - The Courier

Cautious optimism in the vaccine hunt – Cosmos

By Harry Al-Wassiti and Colin Pouton, Monash University, and Kylie Quinn, RMIT University

German biotech company BioNTech and US pharmaceutical Pfizer announced on Monday promising early results from their phase 3 clinical trial for a vaccine against SARS-CoV-2, the virus that causes COVID-19.

These early results are what is known as an interim analysis. Its an early look at the data before a study is complete, to understand if there is any indication of whether the vaccine might work.

Currently, this trial has enrolled 43,538 volunteers, giving half the volunteers two doses of the vaccine and the other half two doses of a placebo. These volunteers then continued their normal lives, but they were monitored for any symptoms that could be COVID-19, with testing to confirm.

Analysis of 94 volunteers with confirmed COVID-19 suggests the vaccine has an efficacy of over 90%.

This means that if you took ten people who were going to get sick from COVID-19 and vaccinated them, only one out of ten would now get sick.

There is more data to come. This is a press release and the data have not undergone peer-review through scientific publication, although it has been assessed by an independent monitoring board. The study also wont be complete until 164 volunteers have confirmed COVID-19, and the estimate of efficacy may therefore change. Finally, the volunteers must be monitored for a defined period of time after vaccination for any side effects and this must be completed.

Important questions also remain. Its unclear how long protection will last, as this study has only been underway for three months. Its unclear if this vaccine protects against severe disease or if this vaccine will work equally well in everyone. For example, a phase 1 clinical trial with this vaccine showed that immune responses were lower in older people.

But 90% efficacy is striking. To give some context, the US Food and Drug Administration indicated they would licence a SARS-CoV-2 vaccine with 50% efficacy. The flu vaccine often provides around 60% efficacy and the mumps vaccine, which is currently the fastest vaccine ever made at four years, provides around 88% efficacy.

The BioNTech/Pfizer vaccine could outstrip that, after just nine months of development. This level of efficacy means virus transmission could be very effectively controlled.

That has the research community excited. It bodes well for other vaccines currently being tested for SARS-CoV-2 and we could end up with multiple successful vaccines. This would be great because some might work better in certain populations, like older people.

Multiple vaccines could also be manufactured using a broad range of established infrastructure, which would accelerate vaccine distribution.

The BioNTech/Pfizer vaccine is whats called an mRNA vaccine.

As this article by Associate Professor Archa Fox, an expert on molecular cell biology from the University of Western Australia, explains:

mRNA vaccines are coated molecules of mRNA, similar to DNA, that carry the instructions for making a viral protein.

After injection into muscle, the mRNA is taken up by cells. Ribosomes, the cells protein factories, read the mRNA instructions and make the viral protein. These new proteins are exported from cells and the rest of the immunisation process is identical to other vaccines: our immune system mounts a response by recognising the proteins as foreign and developing antibodies against them.

A problem for Australia is that it cant make mRNA vaccines onshore yet.

The Australian government has an agreement for ten million doses of the BioNTech/Pfizer vaccine. Since this vaccine requires two doses, this agreement is sufficient for five million Australians. Its unclear how long it will take until any vaccine is widely available, but we may hear more about this in the coming weeks and months.

The vaccine requires storage at a temperature below -60. This will certainly be a challenge for shipping to Australia and local distribution, although not impossible. One solution to this problem is to form vaccination centres to roll out the vaccine once it becomes available. In a briefing by Pfizer, the company said it will use ultra-low temperature shipment strategies and the vaccine can then be distributed on dry-ice.

Currently, Australia has no capacity to produce mRNA on a commercial scale given the technologys novelty. But we (the authors) and others have been working to coordinate and build the manufacturing capacity in Australia for future mRNA vaccine and therapeutics. With financial support aimed at private-public mRNA manufacturing collaboration, Australia can equip itself with this vital technological asset.

Harry Al-Wassiti, Bioengineer and Research Fellow, Monash University; Colin Pouton, Professor of Pharmaceutical Biology, Monash University, and Kylie Quinn, Vice-Chancellors Research Fellow, School of Health and Biomedical Sciences, RMIT University

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Go here to read the rest:
Cautious optimism in the vaccine hunt - Cosmos

Aspiring physician explores the many levels of human health – MIT News

It was her childhood peanut allergy that first sparked senior Ayesha Ngs fascination with the human body. To see this severe reaction happen to my body and not know what was happening that made me a lot more curious about biology and living systems, Ng says.

She didnt exactly plan it this way. But in her three and a half years at MIT, Ng, a biology and cognitive and brain sciences double major from the Los Angeles, California area, has conducted research and taken classes examining just about every level of human health from cellular to societal.

Most recently, her passion for medicine and health equity led her to the National Foundation for the Centers for Disease Control and Prevention (CDC), where, this summer, she worked to develop guidelines for addressing health disparities on state and local health jurisdictions Covid-19 data dashboards. Now, as an aspiring physician amidst the medical school application process, Ng has a sense of how microbiological, physiological, and social systems interact to affect a persons health.

Starting small

Throughout her entire first year at MIT, Ng studied the biology of health at a cellular level. Specifically, she researched the effects of fasting and aging on regeneration of intestinal stem cells, which are located in the human intestinal crypts and continuously self-divide and reproduce. Understanding these metabolic mechanisms is crucial, as their deregulation can lead to age-associated diseases such as cancer.

That experience allowed me to broaden my technical skills, just getting used to so many different types of molecular biological techniques right away, which I really appreciated, Ng says of her time at the Whitehead Institute for Biomedical Research in Professor David Sabatinis lab.

After some time, I realized that I also wanted tostudy sciences at a broader, more macro level, instead of only the microbiology and molecular biology that we were studying in Course 7, Ng says of her biology major.

In addition to studying the biology of cancer, Ng had developed a curiosity about the human brain and how it functions. I was really interested in that, because my grandpa has dementia, Ng says.

Seeing her grandfathers cognitive decline, she was inspired to become involved in MIT BrainTrust, a student organization that offers a social support network for individuals from around the Boston, Massachusetts area who have brain injuries. We have these meetings, in which I serve as one of only one or two students there to facilitate a safe space where we can have all these individuals with brain injury gather, Ng says of the peer-support aspect of the program. They can really share their mutual challenges and experiences.

Investigating the brain

To pursue her interest in brain research and the societal impact of brain injuries, Ng traveled to the University of Hong Kong the summer after her first year as an MIT International Science and Technology Initiatives (MISTI) China Fung Scholar. Working with Professor Raymond Chang, she began to examine neurodegenerative disease and used tissue-clearing techniques to visualize 3D mouse brain structures at cellular resolution. That was personally meaningful for me, to research about that and learn more about dementia, Ng says.

Returning to MIT her sophomore year, Ng was certain that she wanted to continue studying the brain. She began working on Alzheimers research at the MIT Picower Institute for Learning and Memory in the lab of Professor Li-Huei Tsai, the Picower Professor of Neuroscience at MIT. Much existing research into Alzheimers disease has been at the bulk-tissue level, focusing on the neurons role in neurodegeneration associated with aging.

Ngs work with Tsai considers the complexity of alterations across genes and less-abundant cell types, such as microglia, astrocytes, and other supporting glial cells that become dysregulated in the brains of patients with Alzheimers. Considering the interplay between and within cell types during neurodegeneration is most intriguing to her. While some molecular processes are protective, other damaging ones simultaneously occur and can exist even within the same cell type. This intricacy has made the mechanistic basis behind Alzheimers progression elusive and the research that much more crucial.

Its really interesting to see how heterogeneous and complex the responses are in Alzheimer's brains, Ng says of the research program with Tsai, a founding director of MITs Aging Brain Initiative. I really think about these potential new drug targets to improve treatment for Alzheimer's in the future because I have seen, with my grandpa especially, how treatment is really lacking in the neurodegeneration field. Theres no treatment that's been able to stop or even slow the progression of Alzheimer's disease.

Her research project in the Tsai Lab relies on a technology called single-nucleus RNA sequencing (snRNA-seq), which extracts the genomic information contained in individual cells. This is followed by computational dimension reduction and clustering algorithms to examine how Alzheimers disease differentially affects genes and specific cell types.

With that project, we've been able to use single-nucleus RNA sequencing to really look at the brains of human Alzheimer's patients, Ng says. And with the single-cell technology, we're able to look at brain tissue at a much higher resolution, allowing us to see that theres so much heterogeneity within the brain.

After conducting more than a year of Alzheimers research and then taking a human physiology class in her third year, Ng decided to add a second major in brain and cognitive sciences to gain deeper insight specifically into how the nervous system within the body functions.

That class really allowed me to realize that I really love organ systems and wanted to study by looking at more physiological mechanisms, Ng says. It has been really great to, at the end of my college career, really delve more into a very specific system.

Medicine and society

Having gained perspective on cellular and microbiology, and human organ systems, Ng decided to zoom out further, interning this past summer at the National Foundation for the CDC. She found the opportunity through MITs PKG Center, applied as one of 60 candidates, and was selected for a team of four. There, as a member of the CDC Foundations Health Equity Strike Team, she examined how to increase transparency of publicly available Covid-19 data on health disparities and how the narrative tied to health equity can be modified in public health messages. This involved harnessing data about the demographics of those most affected during Covid-19 including how infection and mortality rates differ starkly based on social factors including housing conditions, socioeconomic status, race, and ethnicity.

Thinking about all these factors, we compiled a set of best practices for how to present data about Covid-19, what data should be collected, and tried to push those out to help jurisdictions as best-practice recommendations, Ng says. That did really increase my interest in health equity and made me realize how important public health is as well.

Amidst the Covid-19 pandemic, Ng is spending the first semester of her senior year at home with her family in the Los Angeles area. I really miss the people and not being able to interact with not only other students and peers, but also faculty as well, she says. I really wanted to enjoy time with friends, and just explore more of MIT, too, which I didn't always get the chance to do over the past few years.

Still, she continues to participate in both BrainTrust and MITs Asian Dance team, remotely, through weekly practices on Zoom.

I think dance is one of the biggest de-stressors for me; I had never done dance before going to college. Getting to meet this team and join this community allowed me not only to connect to my Asian cultural roots, but also just expose myself to this new art form where I could really learn how to express myself on stage, Ng says. And that really has been the source of relief for me to just liberate any worries that I have, and has increased my sense of self-awareness and self-confidence.

Armed with the many experiences she has enjoyed at MIT, both in and out of the classroom, Ng plans to continue studying both medicine and public health. Shes excited to explore different potential specialties and is currently most intrigued by surgery. Whichever specialty she may choose, she is determined to include health equity and cultural sensitivity in her practice.

Seeing surgeons, I personally think that being able to physically heal a patient with my own hands, that would be the most rewarding feeling, Ng says. I will strive to, as a physician, use whatever platform that I have to advocate for patients and really drive health-care systems to overcome disparities.

Read more here:
Aspiring physician explores the many levels of human health - MIT News

Magenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer – BioSpace

Nov. 9, 2020 13:00 UTC

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of Steve Mahoney as Chief Financial and Operating Officer.

We welcome Steve to Magenta as a seasoned biotech executive with a strong leadership background, said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. I look forward to partnering with Steve as we continue to grow Magenta and further establish our long-term clinical and commercial operations.

As Chief Financial and Operating Officer, Mr. Mahoney will serve as a member of the Companys Executive Team and will oversee all aspects of financial planning and analysis, as well as investor community engagement, including investor relations and other external stakeholder communications, in addition to R&D capital allocation strategy and operations and facilities management.

Mr. Mahoney comes to Magenta with more than 20 years of global biotechnology sector industry experience. Most recently, Mr. Mahoney served as President and Chief Operating Officer of Kiniksa Pharmaceuticals, Ltd., where the company raised capital in three private financing rounds, an initial public offering and a follow-on financing. Prior to his time at Kiniksa, Mr. Mahoney served as Chief Commercial Officer, among other executive titles of increasing responsibilities, at Synageva Biopharma. Previous to that, he was Regional Director, Legal Asia Pacific Region for Genzyme Corporation, following other roles for the organization.

Mr. Mahoney holds a JD/MBA from Boston College and a BA from Colorado College.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit http://www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as may, will, could, should, expects, intends, plans, anticipates, believes, estimates, predicts, projects, seeks, endeavor, potential, continue or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption Risk Factors in Magentas Annual Report on Form 10-K filed on March 3, 2020, as updated by Magentas most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005177/en/

Excerpt from:
Magenta Therapeutics Appoints Steve Mahoney as Chief Financial and Operating Officer - BioSpace

Does Talaris’ Investigational Cell Therapy Have Potential to Be a ‘Pipeline in a Product’? – BioSpace

Photo courtesy of Talaris.

Talaris Chief Executive Officer Scott Requadt sees FCR001, the companys investigational cell therapy, as a potential pipeline in a product (an experimental treatment that could have multiple uses across a number of indications).

In fact, it was that versatility of the products potential that caused Requadt to join the company as CEO in 2018 after the company, known then as Regenerex, secured $100 million in financing. At the time, Requadt helmed the venture capital group Claris that backed the Series A.

I was really enthusiastic about the company and FCR001, Requadt told BioSpace in an interview.

FCR001, an investigational, allogeneic cell therapy, was previously part of Novartis gene and cell therapy unit, until it was dissolved in 2016. When that unit dissolved, rights to FCR001 reverted to Regenerex. With the return of those rights came multiple opportunities in organ transplant and severe autoimmune disorders. Cell therapies can address complex, multi-pathway diseases and Talaris has big plans for the future of FCR001 to help patients acquire or restore immune tolerance.

Our goal is to basically do for immune tolerance what CAR-T has done for oncology, Requadt said. The same product and the same basic biology will be used. We can treat organ transplant and autoimmune diseases in the same manner.

Through FCR001, Talaris will be able to change the underlying pathology of the disease so the immune system no longer sees it as a threat, Requadt said. The companys lead program is in kidney donor transplant, but FCR001, a one-time stem cell therapy, is also being explored as a treatment for scleroderma, a multi-system autoimmune disease. If FCR001 is effective in these areas, Requadt said those successes will pave the way for use in other indications.

This is a pipeline from a single product, Requadt said of FCR001, which has received a Regenerative Medicine Advanced Therapy designation from the U.S. Food and Drug Administration (FDA).

In July, Kentucky-based Talaris dosed the first patient in its Phase III FREEDOM-1 study of FCR001 in living donor kidney transplant (LDKT) recipients. The trial is expected to enroll 120 adult patients who will receive kidney donations from living donors. The primary endpoint of the study will be the proportion of FCR001 recipients who are free from necessary drugs to maintain immunosuppression without biopsy proven acute rejection at 24 months post-transplant.

Organ transplant patients are required to continue taking drugs to suppress their immune systems to protect the new organ from immune system responses. However, those immunosuppressant treatments drugs are toxic to the kidney and can ultimately kill the transplanted organ in 10 to 15 years. The drugs can also lead to metabolic disorders and cardiovascular issues, Requadt said.

In 2018, Talaris posted positive Phase II data in LDKT recipients, with 70% of patients who received the treatment able to discontinue the use of immunosuppressant drugs. The Phase II data showed that every tolerized patient has been able to remain free of the use of chronic immunosuppressants for up to 10 years. The median follow-up following transplant was five years, with the longest case being a decade. Additionally, Requadt said the company has also seen better kidney functions in recipients who received FCR100 due to the lack of toxicity issues.

While there are other companies exploring similar approaches, Requadt said to his knowledge, no other group has a 10-year data set that demonstrates the safety and efficacy of a treatment like FRC001.

Not only has Talaris seen the impressive results in removing patients from the anchor of immunosuppressant drugs, Requadt said the use of FCR001 decreased the risk of rejection in patients whose biomarkers did not have as high a match with the kidney donors.

In addition to the Phase III study in LDKT patients, Talaris also has plans to conduct a Phase II study in LDKT Delayed Tolerance Induction and will begin research in Deceased Donor Kidney Transplant patients.

Talaris will also use FCR001 in the treatment of diffuse systemic sclerosis (SSc), a severe form of the rare autoimmune disease scleroderma, a rare and potentially fatal chronic autoimmune disease which causes progressive scarring, or fibrosis, of the bodys connective tissues. Autologous hematopoietic stem cell transplant has been shown to halt organ damage and induce remission of the disease. However, with the use of a patients own stem cells, there is a risk of disease recurrence. Also, some patients must undergo full myeloablative conditioning with or without total body irradiation, which is associated with direct organ toxicity and increased risk of future cancers. Talaris aims to harness the power of FCR001 and use stem cells from donors to lower those risks and provide an opportunity for these patients, Requadt said.

For all of these indications were using the same product and were using the same protocols with patients and were treating the patients in the same way. This has the potential to be paradigm shifting, Requadt said.

View original post here:
Does Talaris' Investigational Cell Therapy Have Potential to Be a 'Pipeline in a Product'? - BioSpace

Researchers hope to harness the power of llama nanobodies to treat and prevent COVID-19 – FOX43.com

Llama nanobodies are surprisingly effective at neutralizing the virus, said researchers at the University of Pittsburgh School of Medicine.

PITTSBURGH An unlikely hero has emerged as a potential ally in the fight against COVID-19. Researchers at UPMC are seeing hope for a coronavirus treatment in tiny llama antibodies.

These llama antibodies are called nanobodies and they are much smaller than human antibodies. Their tiny stature gives them the unique ability to latch onto the coronavirus spike protein, blocking the virus from infecting cells.

Dr. Yi Shi, assistant professor of cell biology at the University of Pittsburgh School of Medicine, turned to a llama named Wally to generate these nanobodies. He said they are surprisingly effective at neutralizing the virus.

What we did was we immunized llama Wally with the virus spike protein. Then, it took about 50 to 55 days for Wally to develop nanobodies that can bind very tightly to this virus spike protein, explained Dr. Shi.

Using a mass spectrometry-based technique that Dr. Shi has been perfecting for the past three years, he and his lab team identified the nanobodies in Wallys blood that bind to SARS-CoV-2 most strongly, preventing its spread to cells.

Nanobodies are very stable and potentially could be stored for a long time after production. They can also be delivered by an inhaler directly to the lungs, which makes them particularly promising for respiratory infections such as COVID-19, according to the National Institutes of Health.

Traditional SARS-CoV-2 antibodies require an IV, which dilutes the product throughout the body, necessitating a much larger dose and costing patients and insurers around $100,000 per treatment course, said Dr. Shi.

Dr. Shi said his nanobodies taken from Wally can sit at room temperature for six weeks and can be administered to people via an inhaler or nasal spray to treat or prevent COVID-19. Since SARS-CoV-2 is a respiratory virus, the nanobodies could find and latch onto it in the respiratory system, before it even has a chance to do damage.

I think it is mostly effective for early stage treatment, Dr. Shi added. Basically, preventing the disease from a mild stage to the severe disease.

Dr. Shi said Wally was not harmed during the pre-clinical study. Owners on his farm in Minnesota said Wally is doing great with his llama friends, always coming to greet people when they enter his pen.

Researchers have a long way to go before any treatments are ready for public use. Dr. Shi is hoping to garner enough support to finalize their pre-clinical studies and begin clinical trials for testing.

Link:
Researchers hope to harness the power of llama nanobodies to treat and prevent COVID-19 - FOX43.com

Cell-Free Technology Comes Of Age: BioBits Is Changing The Way We Teach Biology – Forbes

BioBits kits are designed to be used by students and teachers with no biological training. They use ... [+] simple, hands-on experiments, to teach concepts of synthetic and molecular biology. Credit: Wyss Institute at Harvard University (https://wyss.harvard.edu/news/biobits-new-biology-kits-for-a-new-generation-of-kids/)

Hundreds of AP (Advanced Placement) Biology students across eight Boston public schools could be finding a silver lining in online high school. Thanks to a grant from the Massachusetts Life Sciences Center, their curriculum now includes cutting-edge, hands-on biotechnology kits that are being delivered to their doorstep.

Born from a collaboration between MIT and Northwestern University, BioBits is the latest product by miniPCR bio, which specializes in making low-cost biotech equipment for students and scientists alike. Realizing the drastic need for online methods of instruction, they partnered with Mass Insight to develop a BioBits take-home lab activity that teaches AP biology students the central dogma of biology: transcription and translation.

As schools continue to be closed, one thing is increasingly clear: online instruction is hard, not just for students, but also for educators. They are away from their usual workplace. They only interact with the kids through screens. They have very limited opportunities for meaningful engagement and all of a sudden, you open up this little box full of biology, says Sebastian Kraves, Co-Founder of miniPCR.

The safety and accessibility of BioBits is hard to beat. Biology is an expensive field to dabble in, but $100 is enough to provide a classrooms worth of BioBits kits. Since there are no live organisms like bacteria, expensive equipment necessary for the most basic biology lab freezers, incubators, and sterile tools are no longer a limiting factor.

Freeze-dried cell extracts are shelf-stable and can ship worldwide. In the past few months, BioBits kits have been delivered to places outside the United States such as Denmark, Indonesia, and Chile - just to name a few.

Starting next year, they will even make their way to the International Space Station. MiniPCR and Boeing manage the annual Genes in Space challenge, where students will soon be able to submit BioBits experiment ideas, one of which will be selected for an astronaut to conduct on board the ISS.

While the science lesson in these kits is simple: cells make proteins from genes, it begs another question: how is this possible without the living cell itself?

Teachers will stop me and say, wait, wait, I get transcription and translation. But tell me more about that cell-free technology. I didn't realize you could do that, Ally Huang recalls. She and Jessica Stark made the concept of the synthetic biology educational kit a reality during their graduate studies at MIT and Northwestern, respectively.

The core breakthrough is cell-free technology. While it has been used for applications ranging from diagnostics to manufacturing, the way it is making its way into the classroom is a subtle but important shift.

If cell-free technology is robust, safe, and cheap enough for students to tinker with, it could be coming out of lag phase into its exponential growth of potential applications, suggests Dr. Mike Jewett, Professor of Chemical and Biological Engineering at Northwestern.

While the field is still young, substantial effort is being made to increase diversity and equity. This could be one place where synthetic biology could truly embody the values of the twenty-first century.

There's really great research that shows that engagement with science early in a student's career and in meaningful hands-on ways is a great way to get students interested in science. And so I would hope that BioBits and other hands-on activities can be implemented in schools to encourage people from all different backgrounds to pursue careers in STEM, Jessica emphasizes.

The personal backgrounds of the eclectic team behind BioBits shows just how much of an impact access could make.

BioBits kits are designed so that students and teachers with no previous biological training can ... [+] perform their own genetic experiments without the need for expensive and bulky lab equipment, at a fraction of the cost. Credit: Megan Beltran (https://phys.org/news/2018-08-biobits-synthetic-biology-k-students.html)

My favorite gift as a kid was a chemistry kit that I got from my grandmother in the very early 70s, Dr. Jim Collins reminisces. Hes now a Professor of Bioengineering at MIT.

And as a parent of two college-age kids, both interested in science. I introduced them to the chemistry kits, I got the electronic kits, I got the robotic kits, and was really disappointed that there was nothing biological that could be acquired.

Professor Jewett was drawn into biology through the chemistry behind living systems. Ally was fascinated by a fetal pig dissection in high school. Jessica, by the idea that tiny proteins operate every function inside a cell.

Sebastian got a copy of The Voyage of the Beagle from his grandmother at age 12. I did not have any hands on labs. I barely had any science classes. My high school back in Argentina was very resource limited, and also very social sciences oriented. And I went on to study economics. With BioBits, Sebastian is determined to change that narrative.

In sharp contrast to the breakneck increase in our ability to engineer biology, biology education has not changed for generations until, perhaps, now.

Im the founder of SynBioBeta, and some of the companies that I write about are sponsors of the SynBioBeta conference andweekly digest. Thank you toDesiree Hofor additional research and reporting in this article.

See original here:
Cell-Free Technology Comes Of Age: BioBits Is Changing The Way We Teach Biology - Forbes